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Novelty and Impact 
An inverse association between alcohol consumption and the risk of cancer of the renal parenchyma 
has been suggested. Within the European Prospective Investigation into Cancer and Nutrition 
containing nearly 500,000 subjects, we examined the association between alcohol consumption and 
the risk of renal cancers, taking into account cancer subsites. We showed that total alcohol 
consumption at baseline and over lifetime was inversely associated with all renal cancer subsites 
combined and cancers of renal parenchyma.  
  
Abstract  
Epidemiologic studies have reported that moderate alcohol consumption is inversely associated with 
the risk of renal cancer. However, there is no information available on the associations in renal cancer 
subsites. From 1992 through to 2010, 477,325 men and women in the European Prospective 
Investigation into Cancer and Nutrition (EPIC) cohort were followed for incident renal cancers 
(n = 931). Baseline and lifetime alcohol consumption was assessed by country-specific, validated 
dietary questionnaires. Information on past alcohol consumption was collected by lifestyle 
questionnaires. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated from Cox 
proportional hazard models. In multivariate analysis, total alcohol consumption at baseline was 
inversely associated with renal cancer; the HR and 95% CI for the increasing categories of total 
alcohol consumption at recruitment versus the light drinkers category were 0.78 (0.62-0.99), 0.82 
(0.64-1.04), 0.70 (0.55-0.90), 0.91 (0.63-1.30), respectively (ptrend=0.001). A similar relationship was 
observed for average lifetime alcohol consumption, and for all renal cancer subsites combined or for 
renal parenchyma subsite. The trend was not observed in hypertensive individuals and not significant 
in smokers. In conclusion, moderate alcohol consumption was associated with a decreased risk of 





Renal cancers consist of malignant tumors of renal parenchyma and renal pelvis. Adenocarcinoma of 
renal parenchyma (referred to as renal cell carcinoma (RCC)) accounts for over 90% of renal cancers 
while nearly all cancers arising in renal pelvis are of the transitional cell type and comprise less than 
10% of renal cancers 1. The incidence rates of RCC have been increasing over the past decades 2, 
particularly in Western populations 3. This increase has been partly attributed to improvements in 
diagnostic imaging as many patients are diagnosed incidentally from radiographic images obtained for 
other reasons 4. However, 15-25% of patients are still diagnosed with metastatic disease for which the 
survival rates are poor 5. The incidence rates for renal pelvis cancer have leveled or even declined in 
recent years 1. The temporal trends as well as geographic variations in incidence and mortality 6 imply 
a role of environmental or lifestyle factors in the etiology of this cancer. Obesity, hypertension and 
tobacco smoking are recognized risk factors for RCC. Other risk factors, such as dietary components, 
are less clear 7.  
The association between alcohol consumption and the risk of RCC has been widely investigated. 
Some case–control studies 8-10, and earlier cohort studies 11-14 reported no association, while other 
case–control studies 15-20 and prospective cohort studies 21-26 have shown an inverse association 
between alcohol consumption and RCC risk. The largest study to date consisted of a pooled analysis 
of 12 prospective studies and showed that alcohol consumption was associated with a decreased risk 
of RCC 27. Individuals who consumed ≥15 g of alcohol per day had a 28% decreased risk compared 
with non-drinkers. Similar results were reported by three recent meta-analyses. These associations 
were observed for moderate alcohol consumption and RCC risk, while no additional benefits or 
attenuated associations were found for high alcohol consumption 28-30. Some studies also highlighted 
that the inverse association was stronger for wine, particularly among women 15, 18, 27 while others 
showed a more noticeable inverse association for beer 16, 27 or liquors 17, 27. Several reports also 
observed sex-specific associations where regular alcohol consumption was inversely related to risk of 
RCC in women only 15, 16, in men only 25 or in both men and women 17, 24, 27. Cohort studies published 
to date have focused on RCC and were conducted predominantly in North America (US, Canada) and 
Northern Europe (Finland, Sweden and the Netherlands). 
Within the European Prospective Investigation into Cancer and Nutrition (EPIC), we examined the 
association between alcohol consumption (at baseline and over lifetime) and the risk of renal cancers, 
taking into account cancer subsites and alcoholic beverage types in a cohort of nearly half a million 
subjects from 23 centres in 10 Western European countries.  
  
Materials and Methods 
Study population 
EPIC is a multicentre, prospective cohort study designed to investigate the associations between diet, 
lifestyle, and environmental factors and cancer incidence. The rationale, study design, and methods 
of recruitment are described in detail elsewhere; data collected included baseline assessment of 
alcohol drinking and smoking history, anthropometric measurements 31, and diet 32. Briefly, EPIC 
consists of 521,330 men and women recruited from the general population residing in defined 
geographic areas (i.e., town or province) in each of the participating 10 European countries 
(Denmark, France, Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the United 
Kingdom). Exceptions were the Utrecht cohort in the Netherlands (based on women attending breast 
cancer screening), the Spanish cohorts (based mainly on blood donors and civil servants), the Turin 
cohort in Italy (based mainly on blood donors and their spouses), the French cohort (based on women 
covered by a complementary health insurance of the national education system) and the Oxford 
health-conscious sub-cohort (recruited throughout the United Kingdom in order to enroll a large 
number of vegetarians and healthy eaters). The participants were mostly aged between 35 and 70 
years at the time of enrolment (1992–2000). Eligible participants gave written informed consent. 
Ethical review boards from the International Agency for Research on Cancer and local centers 
participating in EPIC approved the study. 
Exclusions 
Subjects with prevalent cancer at any site at entry in the cohort (n = 23,785) and those with missing 
follow-up (n = 4,365) or date at renal cancer diagnosis (n = 1) were excluded. Subjects who had not 
completed the dietary and non-dietary baseline questionnaires (n = 6,253) or were in the top or 
bottom 1% of the ratio of energy intake to estimated energy requirement calculated from body weight, 
height and age 33 were also excluded to reduce the impact on the analysis of implausible extreme 
values (n = 9,601). The final number of EPIC cohort participants available for these analyses was 
477,325.  
Assessment of endpoints 
Incident renal cancer cases were identified by population cancer registries (Denmark, Italy, the 
Netherlands, Spain, Sweden, the United Kingdom, Norway) or by active follow-up (France, Germany, 
Greece), depending on the follow-up system in each of the participating centers. Active follow-up 
used a combination of methods, including health insurance records, cancer and pathology registries, 
and direct contact of participants or next-of-kin. Participants were followed from study entry until renal 
cancer diagnosis, death, emigration, or end of follow-up period. Mortality data were coded following 
the rules of the 10th revision of the International Statistical Classification of Diseases, Injuries and 
Causes of Death (ICD-10), and cancer incidence data following the 3rd revision of the International 
Classification of Diseases for Oncology (ICDO-3). Data were coded according to ICD-10/ICDO-3 as 
carcinoma of the renal parenchyma (C64.9); and carcinoma of the renal pelvis (C65.9), sarcoma and 
unclear or inconsistent subsite (including incoherence between topography and histological codes, 
missing or vague histological code, inconsistence between the level of details and the source of 
information). After a mean follow-up of 11.5 years (range: 0.008–17.8 years), 931 incident cases of 
renal cancer had been reported among the 477,325 participants.  
Assessment of alcohol consumption and other dietary and lifestyle information 
Diet including alcohol consumption over the 12 months before enrolment was measured by center-
specific dietary assessment instruments (mainly food frequency questionnaires (FFQ)) 34. Most 
centers adopted a self-administered dietary questionnaire including 88–266 food items. In each 
country, baseline alcohol consumption was calculated based on intake of alcoholic beverages 
reported in the FFQ. Subjects reported the number of glasses of beer, cider, wine, sweet liquor, 
distilled spirits or fortified wines consumed during the 12 months prior to recruitment. Alcohol 
consumption was calculated based on estimated average glass volume and ethanol content for each 
type of alcoholic beverage, using information collected in 24-hr standardized across all centers dietary 
recalls from a random subset of the cohort 35, 36. Lifetime alcohol consumption up to enrolment was 
assessed as glasses of different beverages consumed at 20, 30, 40, 50 years of age and at baseline 
37. The following EPIC centers and countries did not collect information on past alcohol consumption: 
Naples (Italy), Bilthoven (Netherlands), Sweden, and Norway. Thus, the analysis of lifetime alcohol 
consumption data was conducted on 363,244 participants, including 729 renal cancer cases. Average 
lifetime alcohol consumption was determined as a weighted average of consumption at different ages. 
Never drinkers were defined as subjects who did not report any consumption of alcoholic beverages 
at all points during their lifetime, while those who reported alcohol consumption at ages 20, 30, 40 or 
50 years, but not during the 12 months prior to the recruitment were categorized as former drinkers in 
analyses of lifetime alcohol consumption.  
Statistical analysis 
Hazard ratios (HRs) for the association between alcohol consumption and renal cancers were 
examined using multivariate Cox proportional hazards regression models with age as the time scale 
and adjustment for EPIC study center to control for differences in questionnaires, follow-up 
procedures and other center-specific effects. Alcohol consumption was modelled as a categorical 
variable. The same categories were used for baseline and average lifetime consumption. The 
reference consisted of very light or occasional drinkers (0.1–6 (men); 0.1-3 (women) g/d). All models 
included the following variables: sex, body mass index (BMI) (categories), hypertension (yes/no), 
smoking status (never, former, current, unknown), waist-to-hip ratio (quartiles). For type of alcoholic 
beverage, models were additionally adjusted for other alcoholic beverages (quartiles). Other 
covariates prevalent, including diabetes status, marital status, education level attained, smoking 
intensity and duration, physical activity and energy from non-alcoholic sources, were examined but 
not included in final models as their inclusion did not materially alter the magnitude or confidence 
interval of the results. All analyses were performed combined and separately by sex. To evaluate 
whether the association with alcohol consumption was modulated by other variables, interaction terms 
between alcohol consumption and sex, hypertension, smoking status, diabetes and BMI were 
included in the model, and significance assessed using likelihood ratio tests based on the models with 
and without the interaction terms. Models evaluating baseline wine, beer, liquors and spirits, fortified 
wine consumption were also performed for all renal cancer subsites. Additional analyses were 
performed to assess the associations at baseline of beer only and wine only consumption at baseline. 
To gain more insight into alcohol consumption patterns by geographical region, the associations for 
total baseline and lifetime consumption were evaluated in three European Regions (based on UN 
classification). Tests for trend were performed by ordinal coding of the variable under consideration. 
In addition, participants who reported no consumption of alcohol at baseline were excluded from the 
trend test to check whether this group could bias the dose-response relationship with the exposure. 
The proportional hazards assumption was evaluated on the basis of Schoenfeld residuals after fitting 
the model and using graphical methods. Potential non-linear associations between lifetime and 
baseline alcohol consumption were evaluated by using restricted cubic spline models (using 4 knots) 
and the associated likelihood ratio test in men and women separately, as well as by visual inspection. 
In addition, we conducted a competing risk analysis using Fine and Gray method for Cox regression 
based on multivariate models to compare the sub-hazard of disease-specific risk associations 38. All 
analyses were performed using STATA (version 11.0; StataCorp). All tests were two tailed and 
statistical significance was assessed at the 5% level.  
Results 
Out of a total of 477,325 participants (5,414,027 person-years), 931 renal cancer cases (481 male 
and 450 female cases) were identified. Of these cancers, 678 were located in the renal parenchyma 
(374 male and 304 female cases), 87 in the renal pelvis (43 male and 44 female cases), 5 were 
sarcomas (2 male and 3 female cases) and 161 were of ambiguous or inconsistent subtype (62 male 
and 99 female cases). Table 1 presents the cohort characteristics including country- and sex- specific 
frequencies of renal cancer cases, number of person-years, drinking status as well as mean alcohol 
consumption. Median alcohol consumption at recruitment was 13.9 g/day for men and 5.3 g/day for 
women. Spanish men and Danish women reported the highest median baseline and lifetime alcohol 
consumption. Average daily quantity of alcohol over lifetime was 30.2% higher than baseline 
consumption in men and was 7.5% lower in women. Male participants less frequently reported being 
non-drinkers at recruitment (men: 6.5%; women: 16.4%) and over lifetime (men: 1.6%; women: 
10.4%) than female participants.  
The baseline characteristics of study participants by alcohol consumption at recruitment are 
summarized in Table 2. Male and female participants who were heavy drinkers (consumed ≥ 60 g/day 
of total alcohol at recruitment) more frequently reported being current smokers (49.2% of men, 39.9% 
of women) compared to light drinkers (23.2% of men, 18.6% of women). Both male and female non-
drinkers at recruitment more often declared having history of hypertension and diabetes showing 
31.2% and 7.2% in men and 25.9% and 4.6% in women, respectively.  
The non-linear regression analyses for baseline and lifetime alcohol consumption and renal cancer 
risk for men and women combined are presented in Figures 1 and 2. These non-parametric 
regression analyses showed evidence of nonlinearity in the association between alcohol consumption 
and renal cancer risk in the multivariable model for both baseline (p-value = 0.113) and lifetime 
alcohol consumption (p-value = 0.035). For both baseline and lifetime alcohol consumption a linear 
inverse association was observed in participants with alcohol consumption lower than 10 g/day, this 
relationship became flat above 10 g/day.  
Overall, total baseline and lifetime alcohol consumption were inversely associated with risk of renal 
cancer (Table 3). In the multivariate model, decreased risks (ptrend = 0.001) were observed between 
baseline alcohol consumption and renal cancers combined, compared with light drinkers. This inverse 
trend remained significant when estimated for drinkers only (ptrend = 0.047). Similar hazard ratios were 
observed when diabetes and physical activity were added as covariates to the multivariable model 
(data not shown). The inverse association for baseline alcohol consumption was mostly driven by the 
association in renal parenchyma (ptrend = 0.026) where lower HRs were observed than in renal pelvis. 
The competing risk analysis provided very similar HRs (Supplementary Table 1). Also similar trends 
for inverse association have been found in different geographical regions (Supplementary Table 2).  
We further assessed associations for specific alcoholic beverages, alcohol consumption from beer, 
wine, liquor and spirits for men and women combined (Table 3). Among all cohort participants 18% of 
men and 46% of women were non-beer drinkers, 13% of men and 20% of women were non-wine 
drinkers, and 28% of men and 56% of women were not drinking spirits and liquor beverages. On 
average men had a higher use of alcohol from each beverage for both consumption at recruitment 
and lifetime. The median consumption for beverages (in grams of alcohol from beverage per day) at 
recruitment was: beer 4.8 g/d for men and 0.6 g/d for women, wine 5.1 g/d for men and 3.7 g/d for 
women, liquor and spirits 1.2 g/d for men and 0.4 g/d for women. One type of alcoholic beverage 
alone was not associated with the risk of all renal cancer subsites combined, when adjusted for other 
types of alcoholic beverages. Looking at these associations separately by sex did not show strong 
associations (Supplementary Table 3, Supplementary Table 4). There was however a significant 
inverse association with lifetime consumption of alcohol from liquor and spirits among men (ptrend = 
0.030). A significant inverse association was observed in wine only drinkers, particularly in women 
where a HR of 0.51 (95% CI 0.31-0.84) was observed (Supplementary Table 5). Beer only drinkers 
also showed an inverse association with renal cancer risk, although not significantly.   
Table 4 presents the HRs for renal cancer and alcohol consumption at baseline stratified by sex, 
history of hypertension, smoking status, diabetes and body mass index (BMI). We found an inverse 
association between total alcohol consumption and renal cancer in both sexes with stronger effects in 
women (men: ptrend = 0.057; women: ptrend = 0.003). Interestingly, a lower risk of renal cancer was 
found for participants who declared no history of hypertension. These results were of similar 
magnitude for lifetime consumption (Supplementary Table 6). In addition, the associations between 
baseline and average lifetime alcohol consumption were not modified by sex, hypertension, smoking 
status, diabetes and BMI as evaluated by likelihood ratio test based on models with and without 
interaction term. Non-significant interactions were observed for alcohol consumption and all variables 
(all pinteraction > 0.05).  
Discussion 
In this large prospective European cohort study, we assessed two measures of alcohol consumption. 
These included alcohol consumption at recruitment which evaluates recent consumption only as well 
as alcohol consumption over lifetime. We found that alcohol consumption was inversely associated 
with the risk of renal cancer in men and women. The study supports previous evidence of an inverse 
association between alcohol consumption and the risk of renal cancers. In addition, this study 
evaluated alcohol consumption in different renal cancer subsites including renal parenchyma and 
renal pelvis showing significant inverse associations of moderate alcohol consumption and cancers of 
renal parenchyma. Interestingly, our data also revealed that individuals with self-reported 
hypertension did not present lower risk of renal cancers combined in relation to alcohol consumption.  
Moderate alcohol consumption was inversely associated with renal cancer in our study and supports 
previous reports of case–control and prospective studies that have shown an inverse association 
between alcohol consumption and risk of RCC 15-25, 39, 40. We did not find any clear dose response 
relationship for the main analyses. The inverse association was observed for all renal cancer subsites 
combined and subsite of renal parenchyma. However, other cohort 11-14, 41 and case-control studies 8-
10 have reported no association. These dissimilarities could be due to different methodologies used to 
study alcohol consumption and renal cancer risk, quality of data, sample size and varying categories 
of alcohol consumption.  
Similarly to Lew et al 40 our study found more apparent association of alcohol consumption (both 
baseline and lifetime) with renal cancer in women than in men. These trends (except for risk of 
lifetime alcohol consumption and renal cancer risk in men) were not significant when restricting the 
analysis to drinkers only. The protective effect of alcohol consumption was also observed 
independently of smoking status, diabetes history and body mass index even though the association 
was significant for never and former smokers only. We did not find significant inverse associations for 
participants who reported a history of hypertension contrary to previous pooled analysis.  
Inconsistent results have been reported for types of alcoholic beverages. We observed that inverse 
associations for both alcohol consumptions at recruitment and over lifetime with renal cancer are not 
specific to the type of alcoholic beverages consumed. In addition, we observed a decreased renal 
cancer risk for lifetime consumption of liquor and spirits in men which is consistent with two previous 
studies 17, 27. Due to a small number of cases, we were able to reliably evaluate types of alcoholic 
beverages only for renal parenchyma where similar risk estimates as in all renal cancer sites 
combined were found.  
The mechanism for the inverse association between alcohol consumption and renal cancer risk is not 
well understood but several hypotheses have been postulated. Moderate alcohol consumption is 
associated with a lower risk for type II diabetes and could be related to increased insulin sensitivity 27, 
42. Hyperinsulinemia has been suggested to be associated with risk for RCC 43 and could possibly 
explain the observed inverse association between alcohol and cancer risk. In other words, alcohol 
consumption would prevent insulin resistance, and then indirectly renal cancer. This mechanism, if 
true, would explain that (i) the inverse association is not alcoholic beverage type specific, and (ii) we 
do not observe a dose-response. Another possible mechanism is the diuretic effect of alcohol. 
Increased consumption of fluid may increase urine volume and decrease the exposure of renal 
epithelial cells to carcinogens because of dilution and a shorter duration of exposure 21, 27. The 
relationship between fluid intake and renal cancer was not examined in the present study. However, 
findings from two large cohort studies did not support the hypothesis that greater total fluid intake 
reduced the risk of RCC 24, 44. In a pooled analysis of two US prospective studies and one case-
control study, no association was observed between total fluid intake and risk for RCC 24. Another 
suggested mechanism of protection is a role of antioxidant compounds contained in alcoholic 
beverages. Certain ingredients of alcoholic beverages, such as xanthohumol and resveratrol have 
been shown to have cancer chemopreventive properties 45, 46. However, the amount of antioxidant 
compounds present in alcoholic beverages is too low to be likely to exert a biological effect making 
this hypothesis less probable. Also animal studies demonstrated that moderate ethanol administration 
can provide protection for kidneys in renal ischemia injury through ameliorated oxidative stress as 
shown by increase of antioxidant capacity and decrease of lipid peroxidation 47.  
The strengths of our study include a prospective design that minimizes recall bias of alcohol 
consumption with respect to disease status, large size, inclusion of geographically diverse Western 
European populations, long follow-up, detailed information on potential confounders, and the ability to 
study alcoholic beverage type at baseline and over lifetime. Our study included a large number of 
renal cancer cases and allowed evaluation of baseline and lifetime alcohol consumption at different 
renal cancer subsites.  
Our study also has several limitations. We relied on self-reported information regarding alcohol 
consumption hence we cannot exclude the possibility that some subjects misreported their alcohol 
consumption. However, alcohol consumption as calculated from the food frequency questionnaire 
was highly correlated with consumption assessed by means of a 24-hour dietary recall administered 
in an 8% random sample of participants from each of the 10 countries suggesting high validity and 
reliability of the dietary assessment instruments used 36. Also in the scenario when high consumers 
were falsely categorized as moderate consumers, this could lead to an overestimation of the risk for 
moderate consumers. Furthermore, we cannot rule out the possibility that the association between 
average lifetime alcohol consumption and renal cancer would change if we had information on this 
variable for all participants instead of only 76% of the cohort. However, similar results were observed 
for baseline and lifetime alcohol consumption and renal cancer risk. Our results could also be affected 
by differences in factors other than alcohol consumption. To address this we simultaneously 
controlled for other renal cancer risk factors and performed stratified analyses. However, we cannot 
rule out the possibility of residual confounding.  
In this prospective study, we observed that light to moderate alcohol consumption at recruitment and 
over lifetime is associated with 15% - 30% lower risk of renal cancer. The association was not present 
when restricting the analysis to hypertensive individuals and not significant in smokers. The inverse 
alcohol consumption relationship was observed for all renal cancers combined and cancers of renal 
parenchyma. However, the carcinogenic role of alcohol consumption has been reported for several 
types of cancer, including head and neck cancers, colon, rectum, liver and breast 48-50. Although we 
cannot advocate for alcohol consumption to prevent renal cancer as alcohol has known and multiple 
adverse effects, our results confirming an inverse association warrant further research in the 
mechanisms involved, particularly on the hypothesis of improving insulin sensitivity.  
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Alcohol consumption at 




g/day; median (P10-P90)* 
 Men Women Men Women Men Women Men Women Men Women Men Women 
France 67,386 100.0 -- 59 -- 704,133 -- 13.6 -- 10.4 -- 7.8 (0.9-30.5) -- 4.5 (0.2-18.0) 
Italy 44,541 68.5 44 59 163,353 352,447 4.0 22.3 1.9 1 12.5 1 23.9 (1.0-54.8) 5.9 (0.4-25.7) 21.3 (2.6-49.1)1 4.3 (0.4-18.0)1 
Spain 40,002 62.1 43 24 187,470 306,005 14.4 51.7 3.6 35.0 26.8 (3.5-71.7) 4.7 (0.3-22.4) 35.4 (6.0-91.9) 4.0 (0.3-16.5) 
United Kingdom 75,398 69.7 66 50 260,602 604,165 6.4 6.0 1.1 1.8 8.8 (0.8-35.0) 5.3 (0.4-17.8) 10.5 (1.4-34.1) 5.5 (0.2-20.9) 
The Netherlands 36,505 73.6 16 53 117,401 326,251 8.8 16.5 --2 10.1 1 14.0 (1.4-46.3) 5.5 (0.4-26.2) --2 5.4 (1.3-18.4)1 
Greece 26,032 58.5 16 7 100,430 150,782 10.2 35.4 4.5 28.7 12.2 (1.6-47.8) 2.4 (0.6-12.4) 19.5 (1.7-75.6) 2.2 (0.1-12.8) 
Germany 48,583 56.4 112 48 215,504 279,799 4.0 4.1 0.5 1.4 18.8 (3.0-54.3) 5.5 (0.7-23.5) 19.9 (5.2-55.8) 4.4 (0.9-15.3) 
Sweden 48,692 54.2 82 48 303,452 366,166 7.8 15.2 --2 --2 6.0 (0.8-24.1) 3.0 (0.2-14.6) --2 --2 
Denmark 55,016 52.2 102 63 294,474 330,510 1.8 2.7 0.4 1.4 20.1 (4.8-62.8) 9.9 (1.3-34.9) 16.7 (5.3-41.5) 6.8 (1.1-19.0) 
Norway 35,170 100.0 -- 39 -- 351,083 -- 20.6 -- --2 -- 2.2 (0.5-8.8) -- --2 
All  477,325 70.2 481 450 1,642,686 3,771,341 6.5 16.4 1.6 10.4 13.9 (1.6-61.5) 5.3 (0.5-24.2) 18.1 (3.5-55.6) 4.9 (0.3-18.2) 
* median and percentile (10th - 90th) calculated in drinkers only 
1 Information on lifetime consumption not available for part of the cohort 
2 Information on lifetime consumption not available  
 
  
Table 2. Baseline characteristics of study participants by total alcohol consumption at recruitment, the European Prospective Investigation into Cancer and Nutrition (EPIC) 
cohort, 1992 – 2010. 
 
Cases Non-cases Non-drinkers 
Baseline alcohol consumption, g/d 
Men* > 0 - 6 > 6 - 12 > 12 - 24 > 24 - 60 > 60 
No of participants 481 141,778 9,201 (6.5) 35,914 (25.3) 23,939 (16.8) 29,266 (20.6) 34,576 (24.3) 9,363 (6.6) 
Age at recruitment (years) 57.4 (7.5) 52.2 (10.1) 54.3 (10.8) 51.1 (11.5) 52.0 (10.8) 52.6 (9.7) 52.4 (8.8) 53.0 (7.6) 
Alcohol at baseline (g/d) 20.1 (21.9) 20.3 (23.0) 0.0 (0.0) 2.6 (1.7) 8.9 (1.7) 17.3 (3.5) 37.8 (9.8) 82.3 (25.4) 
Height (m) 175.1 (6.9) 174.7 (7.4) 172.2 (7.6) 174.9 (7.4) 175.4 (7.3) 175.1 (7.2) 174.5 (7.3) 174.2 (7.2) 
Weight (kg) 83.1 (12.7) 80.8 (12.0) 79.6 (12.6) 80.1 (12.4) 80.7 (11.8) 81.0 (11.6) 81.3 (11.6) 83.2 (12.7) 
BMI (kg/m2) 27.1 (3.8) 26.5 (3.6) 26.9 (3.9) 26.2 (3.8) 26.2 (3.6) 26.4 (3.5) 26.7 (3.5) 27.4 (3.9) 
Smoking status (%)         
     Never 27.0 33.0 34.0 42.8 37.8 31.4 24.9 16.4 
     Former 36.8 36.3 34.2 32.0 35.8 39.6 39.5 33.9 
     Current 35.3 29.4 30.1 23.2 24.9 27.9 34.7 49.2 
     Unknown 0.8 1.4 1.8 1.9 1.6 1.2 1.0 0.5 
Hypertension1 (%) 36.1 23.0 31.2 21.9 22.0 22.3 22.9 25.4 
Diabetes1 (%) 5.8 3.7 7.2 4.1 3.2 3.0 3.1 4.1 
Waist circumference1 (cm) 97.2 (10.6) 94.6 (10.2) 95.6 (10.9) 93.7 (10.6) 93.9 (10.0) 94.2 (9.8) 95.1 (9.7) 97.8 (10.5) 
Hip circumference1 (cm) 101.4 (7.5) 100.8 (6.8) 101.4 (7.6) 100.5 (6.9) 100.5 (6.6) 100.6 (6.6) 101.0 (6.7) 101.9 (7.4) 
Waist-hip-ratio1 0.96 (0.07) 0.94 (0.06) 0.94 (0.07) 0.93 (0.07) 0.93 (0.06) 0.94 (0.06) 0.94 (0.06) 0.96 (0.06) 
         
Women*    > 0 - 3 > 3 - 12 > 12 - 24 > 24 - 60 > 60 
No of participants 450 334,616 54,933 (16.4) 107,291 (32) 100,238 (29.9) 44,167 (13.2) 26,261 (7.8) 2,176 (0.7) 
Age at recruitment (years) 56.3 (7.9) 50.8 (9.8) 52.3 (9.4) 50.2 (10.2) 50.4 (9.9) 51.0 (9.6) 51.7 (8.5) 51.8 (8.1) 
Alcohol at baseline (g/d) 7.5 (13.5) 7.9 (11.6) 0.0 (0.0) 1.2 (0.8) 6.9 (2.6) 16.7 (3.6) 34.8 (8.8) 76.2 (17.3) 
Height (m) 162.1 (6.4) 162.3 (6.7) 159.9 (7.0) 162.5 (6.7) 163.0 (6.5) 162.6 (6.5) 163.0 (6.3) 163.6 (6.1) 
Weight (kg) 68.9 (13.0) 65.7 (11.7) 67.5 (12.8) 66.3 (12.3) 65.0 (11.0) 64.1 (10.3) 64.4 (10.5) 65.8 (11.4) 
BMI (kg/m2) 26.2 (4.6) 25.0 (4.4) 26.5 (5.1) 25.1 (4.6) 24.5 (4.1) 24.2 (3.8) 24.2 (3.8) 24.6 (4.0) 
Smoking status (%)         
     Never 50.7 55.7 65.6 57.9 54.1 51.0 41.4 32.5 
     Former 22.2 22.5 14.4 21.2 25.6 26.4 28.4 24.5 
     Current 26.2 19.5 17.6 18.6 18.3 20.5 28.1 39.9 
     Unknown 0.9 2.3 2.4 2.3 2.5 2.1 2.2 3.2 
Hypertension1 (%) 40.0 20.0 25.9 20.4 18.1 17.6 17.6 21.6 
Diabetes1 (%) 3.8 2.3 4.6 2.4 1.6 1.5 1.6 2.5 
Waist circumference1 (cm) 84.0 (12.2) 80.1 (11.4) 84.9 (12.4) 80.1 (11.7) 78.6 (10.7) 78.3 (10.1) 79.2 (10.3) 82.0 (11.5) 
Hip circumference1 (cm) 102.8 (9.7) 101.0 (9.3) 104.1 (10.3) 101.4 (9.6) 100.1 (8.7) 99.5 (8.1) 99.7 (8.1) 100.3 (8.7) 
Waist-hip-ratio1 0.82 (0.08) 0.79 (0.07) 0.81 (0.07) 0.79 (0.07) 0.78 (0.07) 0.79 (0.07) 0.79 (0.07) 0.82 (0.08) 
         
All Participants (n, %) 931 476,394 64,134 (13.4) 143,205 (30.0) 124,177 (26.0) 73,433 (15.4) 60,837 (12.8) 11,539 (2.4) 
*Continuous variables are presented as means and standard deviations (SD), categorical variables are presented as percentages. 
1 Unknown values were excluded from the calculations.  
Percent of missing data were for hypertension, 13.2%; diabetes, 3.5%; waist circumference, 22.4%; hip circumference, 22.4%; waist-hip ratio, 22.4%. 
  
Table 3. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CIs) for renal cancer in relation to 
baseline and lifetime alcohol consumption in the European Prospective Investigation into Cancer and Nutrition (EPIC) 
study, 1992-2010. 
 Total renal cancer Renal parenchyma Renal pelvis 
Alcohol consumption Casesc HR (95% CI)a Cases HR (95% CI)a Cases HR (95% CI)a 
    Baseline (g/d)       
        Non-drinkers 83 1.21 (0.91-1.59) 56 1 (0.72-1.39) 11 2.67 (1.05-6.83) 
      > 0 - 6 (M) / > 0 - 3 (W) 170 Reference 131 Reference 10 Reference 
      > 6 - 12 (M) / > 3 - 12 (W) 120 0.78 (0.62-0.99) 92 0.80 (0.61-1.04) 11 1.00 (0.42-2.37) 
      > 12 - 24 118 0.82 (0.64-1.04) 80 0.72 (0.54-0.96) 15 1.47 (0.65-3.33) 
      > 24 - 60 116 0.70 (0.55-0.90) 86 0.67 (0.50-0.89) 10 0.88 (0.36-2.19) 
      > 60 41 0.91 (0.63-1.30) 34 0.98 (0.66-1.46) 3 0.92 (0.24-3.53) 
          P-trendd 
 0.001  0.026  0.112 
    Average lifetime (g/d)       
        Non-drinkers 42 1.44 (0.99-2.08) 27 1.19 (0.76-1.86) 5 3.04 (0.88-10.55) 
        Former 31 1.05 (0.70-1.57) 21 0.90 (0.56-1.46) 4 2.00 (0.56-7.09) 
      > 0 - 6 (M) / > 0 - 3 (W) 136 Reference 102 Reference 8 Reference 
      > 6 - 12 (M) / > 3 - 12 (W) 125 0.73 (0.57-0.93) 85 0.66 (0.49-0.88) 21 1.59 (0.70-3.61) 
      > 12 - 24 125 0.86 (0.66-1.11) 92 0.84 (0.62-1.13) 10 0.84 (0.32-2.19) 
      > 24 - 60 104 0.76 (0.57-1.00) 78 0.73 (0.53-1.02) 7 0.67 (0.23-1.96) 
      > 60 32 0.94 (0.61-1.44) 28 1.04 (0.65-1.67) 1 0.43 (0.05-3.83) 
          P-trendd  0.007  0.138  0.018 
Baseline alcohol consumption by types of alcoholic beverageb   
Beer (g/d)       
        Non-drinkers 211 1.23 (0.94-1.60) 156 1.16 (0.86-1.57) 18 1.70 (0.59-4.95) 
      Q1 (> 0 – 0.43) 98 Reference 80 Reference 5 Reference 
      Q2 (> 0.43 – 1.37) 68 1.12 (0.81-1.54) 55 1.15 (0.80-1.65) 7 1.98 (0.60-6.49) 
      Q3 (> 1.37 – 5.27) 90 0.99 (0.73-1.35) 57 0.73 (0.51-1.05) 8 1.86 (0.57-6.02) 
      Q4 (> 5.27) 181 0.96 (0.72-1.29) 131 0.83 (0.59-1.15) 22 2.19 (0.73-6.59) 
          P-trendd  0.093  0.012  0.418 
Wine (g/d)       
        Non-drinkers 92 1.13 (0.84-1.52) 64 0.98 (0.69-1.38) 10 1.89 (0.68-5.24) 
      Q1 (> 0 – 0. 98) 125 Reference 93 Reference 8 Reference 
      Q2 (> 0. 98 – 4.42) 156 1.09 (0.86-1.39) 118 1.08 (0.82-1.42) 15 1.52 (0.64-3.62) 
      Q3 (> 4.42 – 9.76) 127 0.96 (0.75-1.24) 88 0.90 (0.67-1.22) 15 1.36 (0.56-3.29) 
      Q4 (> 9.76) 148 0.89 (0.68-1.16) 116 0.89 (0.66-1.22) 12 1.01 (0.39-2.64) 
          P-trendd  0.119  0.416  0.420 
Liquor and spirits (g/d)       
        Non-drinkers 228 0.94 (0.70-1.26) 168 0.99 (0.70-1.40) 22 2.08 (0.64-6.78) 
      Q1 (> 0 – 0. 17) 78 Reference 53 Reference 4 Reference 
      Q2 (> 0. 17 – 0. 63) 115 0.89 (0.65-1.22) 89 0.94 (0.65-1.35) 11 1.96 (0.58-6.65) 
      Q3 (> 0. 63 – 2.11) 100 0.82 (0.59-1.13) 65 0.78 (0.53-1.15) 15 1.92 (0.59-6.22) 
      Q4 (> 2.11) 127 0.88 (0.64-1.20) 104 1.04 (0.72-1.51) 8 0.89 (0.25-3.21) 
          P-trendd  0.370  0.863  0.207 
Average lifetime alcohol consumption by types of alcoholic beverageb   
Beer (g/d)       
        Non-drinkers 138 1.33 (0.97-1.82) 93 1.22 (0.84-1.77) 13 1.07 (0.41-2.82) 
      Q1 (> 0 – 0. 30) 67 Reference 49 Reference 8 Reference 
      Q2 (> 0. 30 - 1.34) 87 1.03 (0.74-1.43) 68 1.01 (0.69-1.47) 10 0.97 (0.37-2.51) 
      Q3 (> 1.34– 4.83) 109 1.14 (0.81-1.59) 79 1.09 (0.74-1.61) 10 0.57 (0.20-1.57) 
      Q4 (> 4.83) 194 1.30 (0.92-1.85) 144 1.26 (0.84-1.90) 15 0.60 (0.21-1.72) 
          P-trendd  0.964  0.798  0.194 
Wine (g/d)       
        Non-drinkers 70 1.21 (0.89-1.66) 46 1.07 (0.73-1.56) 7 1.70 (0.57-5.02) 
      Q1 (> 0 – 1.10) 121 Reference 89 Reference 8 Reference 
      Q2 (>1.10 – 3.47) 138 1.04 (0.81-1.33) 103 1.01 (0.76-1.35) 14 1.50 (0.62-3.61) 
      Q3 (> 3.47 – 8.70) 123 0.98 (0.75-1.27) 84 0.90 (0.66-1.23) 15 1.41 (0.58-3.45) 
      Q4 (> 8.70) 143 0.91 (0.69-1.20) 111 0.91 (0.66-1.26) 12 0.97 (0.36-2.61) 
          P-trendd  0.132  0.325  0.540 
Liquor and spirits (g/d)       
        Non-drinkers 143 1.10 (0.81-1.48) 99 1.14 (0.8-1.64) 13 0.99 (0.39-2.51) 
      Q1 (> 0 – 0. 14) 85 Reference 57 Reference 11 Reference 
      Q2 (> 0. 14 – 1.02) 122 1.11 (0.83-1.49) 89 1.11 (0.78-1.58) 8 1.06 (0.41-2.70) 
      Q3 (> 1.02 – 3.28) 113 0.87 (0.65-1.17) 83 0.90 (0.63-1.29) 14 1.11 (0.49-2.53) 
      Q4 (> 3.28) 132 0.86 (0.64-1.17) 105 0.97 (0.68-1.40) 10 0.75 (0.29-1.92) 
          P-trendd  0.085  0.311  0.707 
a Multivariate model with age at recruitment (continuous) as the time scale stratified by EPIC study center and adjusted by sex 
(Male, Female), body mass index (categories: <18.5, 18.5-<25, 25-<30, 30-<35, ≥35), smoking status (Never/Former/Current/Don’t 
know), hypertension (Yes/No/Don’t know), waist-to-hip ratio (quartiles). For type of alcoholic beverage, models were additionally 
adjusted for other alcoholic beverages (quartiles)  
b Quartiles for types of alcohol beverages including beer, wine, liquors and spirits were calculated separately for baseline and 
lifetime alcohol consumption among consumers only 
c Number of cases indicates the number of cases with data available for the complete set of variables used in multivariable model; 
the numbers for all renal cancer subsites include 161 unclear or inconsistent subsite cases and 5 sarcoma cases for which 
separate subsite analysis was not performed  
d Tests for trend were performed by ordinal coding of the variable under consideration 
Table 4. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CIs) for renal cancer by predefined categories of baseline alcohol 
consumption, according to sex, history of hypertension, smoking status, diabetes status and body mass index (BMI) in the European Prospective 
Investigation into Cancer and Nutrition (EPIC) study, 1992-2010. 




 Non-drinkers > 0 - 6 > 6 - 12 > 12 - 24 > 24 - 60 > 60 P-interactiong 
  > 0 - 3 > 3 - 12 > 12 - 24 > 24 - 60 > 60  
Sexa        0.377 
    Male         
        Cases (n) e 24 80 56 83 96 35   
        Multivariate model 1.05 (0.66-1.67) Reference 0.85 (0.60-1.20) 0.86 (0.63-1.18) 0.73 (0.54-0.99) 0.83 (0.55-1.26) 0.057  
    Female         
        Cases (n) e 59 90 64 35 20 6   
        Multivariate model 1.36 (0.95-1.94) Reference 0.72 (0.52-1.00) 0.75 (0.51-1.12) 0.64 (0.39-1.04) 2.19 (0.94-5.08) 0.003  
Hypertensionb        0.162 
    No         
        Cases (n) e 40 107 58 70 69 25   
        Multivariate model 1.10 (0.75-1.62) Reference 0.59 (0.43-0.82) 0.71 (0.52-0.96) 0.59 (0.43-0.82) 0.81 (0.51-1.29) 0.002  
    Yes         
        Cases (n) e 42 59 57 42 41 14   
        Multivariate model 1.42 (0.94-2.15) Reference 1.14 (0.79-1.65) 1.00 (0.67-1.50) 0.90 (0.59-1.37) 1.12 (0.60-2.06) 0.161  
Smoking statusc        0.838 
    Never         
        Cases (n) e 41 79 52 39 23 6   
        Multivariate model 1.02 (0.68-1.53) Reference 0.79 (0.55-1.12) 0.78 (0.53-1.16) 0.53 (0.32-0.86) 0.81 (0.35-1.92) 0.020  
    Former         
        Cases (n) e 23 43 40 40 42 13   
        Multivariate model 1.82 (1.08-3.07) Reference 0.95 (0.61-1.46) 0.89 (0.57-1.38) 0.82 (0.53-1.28) 1.07 (0.56-2.03) 0.029  
    Current         
        Cases (n) e 19 47 28 39 51 22   
        Multivariate model 1.12 (0.65-1.94) Reference 0.65 (0.4-1.03) 0.84 (0.55-1.30) 0.80 (0.53-1.20) 0.94 (0.55-1.60) 0.340  
Body mass indexd        0.066 
    < 25         
        Cases (n) e 24 45 50 46 31 8   
        Multivariate model 1.63 (0.98-2.73) Reference 1.13 (0.75-1.70) 1.13 (0.74-1.73) 0.76 (0.47-1.22) 0.90 (0.41-1.96) 0.042  
    25 - <30         
        Cases (n) e 31 84 45 50 59 27   
        Multivariate model 0.93 (0.61-1.43) Reference 0.58 (0.40-0.83) 0.65 (0.45-0.93) 0.65 (0.46-0.93) 1.16 (0.73-1.84) 0.184  
    ≥ 30         
        Cases (n) e 28 41 25 22 26 6   
        Multivariate model 1.25 (0.75-2.10) Reference 0.79 (0.48-1.31) 0.82 (0.48-1.39) 0.78 (0.46-1.31) 0.45 (0.18-1.09) 0.023  
a Multivariate model with age at recruitment (continuous) as the time scale stratified by EPIC study center and adjusted by body mass index (categories: <18.5, 18.5-<25, 25-
<30, 30-<35, ≥35), smoking status (Never/Former/Current/Don’t know), hypertension (Yes/No/Don’t know), waist-to-hip ratio (quartiles) 
b Multivariate model with age at recruitment (continuous) as the time scale stratified by EPIC study center and adjusted by sex (Male, Female), body mass index (categories: 
<18.5, 18.5-<25, 25-<30, 30-<35, ≥35), smoking status (Never/Former/Current/Don’t know), waist-to-hip ratio (quartiles) 
c Multivariate model with age at recruitment (continuous) as the time scale stratified by EPIC study center and adjusted by sex (Male, Female), body mass index (categories: 
<18.5, 18.5-<25, 25-<30, 30-<35, ≥35), hypertension (Yes/No/Don’t know), waist-to-hip ratio (quartiles) 
d Multivariate model with age at recruitment (continuous) as the time scale stratified by EPIC study center and adjusted by sex (Male, Female), smoking status 
(Never/Former/Current/Don’t know), hypertension (Yes/No/Don’t know), waist-to-hip ratio (quartiles) 
e Number of cases indicates the number of cases with data available for the complete set of variables used in multivariable model and include all renal cancer subsites of renal 
parenchyma, renal pelvis, sarcoma and unclear or inconsistent subsite 
f Tests for trend were performed by ordinal coding of the variable under consideration 




Figure 1. Hazard Ratios (solid line) and 95% Confidence Intervals (grey shade) for baseline alcohol 
consumption and renal cancer risk evaluated using restricted cubic spline regression (4 knots) for 
men and women combined in the EPIC cohort. Participants with extreme alcohol consumption of 
more than 60 g/day and non-drinkers were excluded. The model was adjusted for age at recruitment, 
hypertension, sex, body mass index, smoking status, waist-to-hip ratio and stratified by center. 
European Prospective Investigation into Cancer and Nutrition (EPIC), 1992-2010.  
Figure 2. Hazard Ratios (solid line) and 95% Confidence Intervals (grey shade) for lifetime alcohol 
consumption and renal cancer risk evaluated using restricted cubic spline regression (4 knots) for 
men and women combined in the EPIC cohort. Participants with extreme alcohol consumption of 
more than 60 g/day and non-drinkers were excluded. The model was adjusted for age at recruitment, 
hypertension, sex, body mass index, smoking status, waist-to-hip ratio and stratified by center. 
European Prospective Investigation into Cancer and Nutrition (EPIC), 1992-2010. 
  
Supplementary Table 1. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals 
(CIs) for renal cancer by predefined categories of baseline and lifetime alcohol consumption by 
competing risk analysis (using Fine and Gray method) in the European Prospective Investigation into 
Cancer and Nutrition (EPIC) study, 1992-2010. 
 Multivariate model Competing risk 
analysis 
Alcohol consumptionb Casesb HR (95% CI)a HR (95% CI)a 
Total alcohol consumption    
    Baseline (g/d)    
        Non-drinkers 83 1.21 (0.91-1.59) 0.99 (0.76-1.29) 
        > 0 - 6 (M) / > 0 - 3 (W) 170 Reference Reference 
        > 6 - 12 (M) / > 3 - 12 (W) 120 0.78 (0.62-0.99) 0.79 (0.62-1.00) 
        > 12 - 24 118 0.82 (0.64-1.04) 0.84 (0.66-1.07) 
        > 24 - 60 116 0.71 (0.55-0.91) 0.73 (0.57-0.94) 
        > 60 41 0.91 (0.64-1.31) 0.91 (0.63-1.30) 
          P-trendc  0.001 0.044 
    Average lifetime (g/d)    
        Non-drinkers 42 1.44 (0.99-2.08) 1.1 (0.77-1.57) 
        Former 31 1.05 (0.70-1.57) 0.88 (0.60-1.31) 
        > 0 - 6 (M) / > 0 - 3 (W) 136 Reference Reference 
        > 6 - 12 (M) / > 3 - 12 (W) 125 0.73 (0.57-0.93) 0.75 (0.58-0.95) 
        > 12 - 24 125 0.86 (0.66-1.11) 0.86 (0.67-1.12) 
        > 24 - 60 104 0.76 (0.57-1.00) 0.75 (0.57-1.00) 
        > 60 32 0.94 (0.61-1.44) 0.82 (0.55-1.24) 
          P-trendc  0.007 0.058 
a Multivariate model with age at recruitment (continuous) as the time scale stratified by EPIC study center and 
adjusted by sex (Male, Female), body mass index (categories: <18.5, 18.5-<25, 25-<30, 30-<35, ≥35), smoking 
status (Never/Former/Current/Don’t know), hypertension (Yes/No/Don’t know), waist-to-hip ratio (quartiles) 
b Number of cases indicates the number of cases with data available for the complete set of variables used in 
multivariable model and include all renal cancer subsites of renal parenchyma, renal pelvis, sarcoma and unclear 
or inconsistent subsite 
c Tests for trend were performed by ordinal coding of the variable under consideration 
Supplementary Table 2. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CIs) for renal cancer in relation to baseline and lifetime 
alcohol consumption stratified by geographic regions in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, 1992-2010. 
  Total Northern Europea Southern Europea Western Europea 
Alcohol consumption Casesb HR (95% CI)c Casesb HR (95% CI)c Casesb HR (95% CI)c Casesb HR (95% CI)c 
Total alcohol consumption 
            Baseline (g/d) 
                Non-drinkers 83 1.21 (0.91-1.59) 11 0.84 (0.43-1.60) 44 1.1 (0.72-1.69) 28 1.74 (1.09-2.78) 
        > 0 - 6 (M) / > 0 - 3 (W) 170 Reference 66 Reference 49 Reference 55 Reference 
        > 6 - 12 (M) / > 3 - 12 (W) 120 0.78 (0.62-0.99) 54 0.77 (0.53-1.11) 24 0.83 (0.51-1.35) 42 0.77 (0.52-1.16) 
        > 12 - 24 118 0.82 (0.64-1.04) 48 0.76 (0.51-1.12) 25 0.74 (0.45-1.20) 45 0.96 (0.64-1.43) 
        > 24 - 60 116 0.70 (0.55-0.90) 45 0.70 (0.47-1.05) 33 0.62 (0.39-0.99) 38 0.79 (0.51-1.22) 
        > 60 41 0.91 (0.63-1.30) 14 0.74 (0.40-1.35) 18 1.28 (0.72-2.29) 9 0.75 (0.36-1.54) 









    Average lifetime (g/d) 
                Non-drinkers 42 1.44 (0.99-2.08) 4 1.57 (0.56-4.37) 27 1.08 (0.65-1.78) 11 2.45 (1.2-4.98) 
        Former 31 1.05 (0.70-1.57) 3 0.58 (0.18-1.87) 15 0.80 (0.44-1.46) 13 1.72 (0.90-3.28) 
        > 0 - 6 (M) / > 0 - 3 (W) 136 Reference 53 Reference 45 Reference 38 Reference 
        > 6 - 12 (M) / > 3 - 12 (W) 125 0.73 (0.57-0.93) 54 0.71 (0.48-1.05) 20 0.49 (0.29-0.83) 51 0.97 (0.64-1.49) 
        > 12 - 24 125 0.86 (0.66-1.11) 62 1.00 (0.68-1.49) 23 0.64 (0.38-1.07) 40 0.86 (0.53-1.39) 
        > 24 - 60 104 0.76 (0.57-1.00) 34 0.79 (0.49-1.26) 39 0.71 (0.43-1.17) 31 0.74 (0.44-1.25) 
        > 60 32 0.94 (0.61-1.44) 3 0.66 (0.20-2.16) 21 0.93 (0.50-1.72) 8 0.86 (0.39-1.92) 
          P-trendd   0.007   0.540   0.162   0.004 
a Northern Europe region includes: United Kingdom, Sweden, Denmark, Norway; Southern Europe region includes: Italy, Spain, Greece; Western Europe region includes: 
France, The Netherlands, Germany 
b Number of cases indicates the number of cases with data available for the complete set of variables used in multivariable model; the numbers for all renal cancer subsites 
include 161 unclear or inconsistent subsite cases and 5 sarcoma cases for which separate subsite analysis was not performed  
c Multivariate model with age at recruitment (continuous) as the time scale stratified by EPIC study center and adjusted by sex (Male, Female), body mass index (categories: 
<18.5, 18.5-<25, 25-<30, 30-<35, ≥35), smoking status (Never/Former/Current/Don’t know), hypertension (Yes/No/Don’t know), waist-to-hip ratio (quartiles). For type of 
alcoholic beverage, models were additionally adjusted for other alcoholic beverages (quartiles)  
d Tests for trend were performed by ordinal coding of the variable under consideration 
 
Supplementary Table 3. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals 
(CIs) for renal cancer by quartiles of baseline alcohol consumption from alcoholic beverages stratified 
by sex in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, 1992-2010. 
              
 
HR (95% CI) for categories of baseline alcoholic beverages consumption (g/d)a 
P-trendd 
  Non-drinkers Q1 Q2 Q3 Q4 
Beerb 
      
   Male 
      
Cases (n)c 75 38 45 63 153 
 
Multivariate model 1.26 (0.81-1.95) Reference 1.39 (0.88-2.20) 1.12 (0.72-1.73) 0.99 (0.65-1.50) 0.237 
  Female       
Cases (n) 136 60 23 27 28 
 
Multivariate model 1.17 (0.84-1.65) Reference 0.80 (0.49-1.32) 0.83 (0.52-1.33) 1.18 (0.72-1.92) 0.348 
Wineb       
   Male       
Cases (n)c 33 65 84 84 108  
Multivariate model 0.95 (0.61-1.50) Reference 1.07 (0.77-1.49) 1.08 (0.77-1.51) 0.80 (0.56-1.15) 0.359 
  Female       
Cases (n)c 59 60 72 43 40  
Multivariate model 1.32 (0.89-1.97) Reference 1.11 (0.78-1.57) 0.79 (0.53-1.19) 1.00 (0.66-1.53) 0.137 
Liquor and spiritsb       
   Male       
Cases (n)c 94 31 69 78 102  
Multivariate model 0.94 (0.60-1.49) Reference 0.88 (0.56-1.41) 0.95 (0.60-1.51) 0.89 (0.57-1.40) 0.744 
  Female       
Cases (n)c 134 47 46 22 25  
Multivariate model 1.01 (0.68-1.50) Reference 1.03 (0.66-1.61) 0.60 (0.36-1.02) 0.96 (0.58-1.59) 0.284 
a Multivariate model with age at recruitment (continuous) as the time scale stratified by EPIC study center and 
adjusted by body mass index (categories: <18.5, 18.5-<25, 25-<30, 30-<35, ≥35), smoking status 
(Never/Former/Current/Don’t know), hypertension (Yes/No/Don’t know), waist-to-hip ratio (quartiles) and other 
alcoholic beverages (quartiles) 
b Quartiles for types of alcohol beverages including beer, wine, liquors and spirits were calculated separately for 
baseline alcohol consumption among consumers only 
c Number of cases indicates the number of cases with data available for the complete set of variables used in 
multivariable model and include all renal cancer subsites of renal parenchyma, renal pelvis, sarcoma and unclear 
or inconsistent subsite 
d Tests for trend were performed by ordinal coding of the variable under consideration 
 
 
Supplementary Table 4. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals 
(CIs) for renal cancer by quartiles of lifetime alcohol consumption from alcoholic beverages stratified 
by sex in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, 1992-2010 
 
      
 
HR (95% CI) for categories of lifetime alcoholic beverages consumption (g/d)a 
P-trendd 
  Non-drinkers Q1 Q2 Q3 Q4 
Beerb 
     
 
   Male 
      
Cases (n)c 33 17 38 73 182 
 
Multivariate model 1.25 (0.67-2.33) Reference 1.07 (0.59-1.92) 1.27 (0.73-2.21) 1.55 (0.89-2.69) 0.137 
  Female 
      
Cases (n)c 105 50 49 36 12 
 
Multivariate model 1.40 (0.97-2.03) Reference 0.98 (0.65-1.48) 1.08 (0.68-1.70) 1.17 (0.60-2.26) 0.199 
Wineb 
     
 
   Male 
      
Cases (n)c 21 63 73 82 104 
 
Multivariate model 1.02 (0.62-1.69) Reference 1.00 (0.71-1.41) 1.12 (0.79-1.58) 0.82 (0.56-1.18) 0.392 
  Female 
      
Cases (n)c 49 58 65 41 39 
 
Multivariate model 1.42 (0.93-2.16) Reference 1.07 (0.75-1.54) 0.79 (0.52-1.20) 1.05 (0.68-1.62) 0.149 
Liquor and spiritsb 
     
 
   Male 
      
Cases (n)c 43 37 68 78 117 
 
Multivariate model 1.11 (0.69-1.78) Reference 1.22 (0.8-1.87) 0.82 (0.54-1.23) 0.80 (0.53-1.21) 0.030 
  Female 
      
Cases (n)c 100 48 54 35 15 
 
Multivariate model 1.09 (0.73-1.62) Reference 1.01 (0.67-1.52) 0.99 (0.63-1.55) 1.02 (0.56-1.84) 0.717 
a Multivariate model with age at recruitment (continuous) as the time scale stratified by EPIC study center and 
adjusted body mass index (categories: <18.5, 18.5-<25, 25-<30, 30-<35, ≥35), smoking status 
(Never/Former/Current/Don’t know), hypertension (Yes/No/Don’t know), waist-to-hip ratio (quartiles) 
b Quartiles for types of alcohol beverages including beer, wine, liquors and spirits were calculated separately for 
lifetime alcohol consumption among consumers only 
c Number of cases indicates the number of cases with data available for the complete set of variables used in 
multivariable model and include all renal cancer subsites of renal parenchyma, renal pelvis, sarcoma and unclear 
or inconsistent subsite 




Supplementary Table 5. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals 
(CIs) for renal cancer by status of baseline alcohol consumption from alcoholic beverages for beer or 
wine drinkers only stratified by sex in the European Prospective Investigation into Cancer and 
Nutrition (EPIC) study, 1992-2010 
HR (95% CI) for baseline alcoholic beverages consumption statusa 
  Non-drinkers Drinkers P-value 
Beerb 
   Cases (n)c 83 21 
 Multivariate model Reference 0.75 (0.45-1.26) 0.284 
Sex 
   
   Male 
   
Cases (n)c 24 12 
 
Multivariate model Reference 0.82 (0.4-1.7) 0.592 
  Female 
   
Cases (n)c 59 9 
 
Multivariate model Reference 0.73 (0.35-1.52) 0.405 
    
Wineb 
  
 Cases (n)c 83 44 
 Multivariate model Reference 0.66 (0.45-0.96) 0.031 
Sex 
   
   Male 
   
Cases (n)c 24 19 
 
Multivariate model Reference 0.87 (0.45-1.66) 0.67 
  Female 
   
Cases (n)c 59 25 
 
Multivariate model Reference 0.51 (0.31-0.84) 0.008 
a Multivariate model with age at recruitment (continuous) as the time scale stratified by EPIC study center and 
adjusted by sex, body mass index (categories: <18.5, 18.5-<25, 25-<30, 30-<35, ≥35), smoking status 
(Never/Former/Current/Don’t know), hypertension (Yes/No/Don’t know), waist-to-hip ratio (quartiles)  
b The status for type of alcohol beverage. For beer, drinkers of wine, liquors, spirits and fortified wine were 
excluded. For wine, drinkers of beer, liquors, spirits and fortified wine were excluded. 
c Number of cases indicates the number of cases with data available for the complete set of variables used in 
multivariable model and include all renal cancer subsites of renal parenchyma, renal pelvis, sarcoma and unclear 
or inconsistent subsite for beer- or wine-drinkers only 
  
Supplementary Table 6. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CIs) for renal cancer by predefined categories of lifetime 
alcohol consumption, according to sex, history of hypertension, smoking status, diabetes status and body mass index (BMI) in the European Prospective 
Investigation into Cancer and Nutrition (EPIC) study, 1992-2010. 
 
HR (95% CI) for categories of lifetime alcohol consumption (g/d) 
P-trendf 
 
 Non-drinkers Former 
 > 0 - 6 > 6 - 12 > 12 - 24 > 24 - 60 > 60 P-interactiong 
  > 0 - 3 > 3 - 12 > 12 - 24 > 24 - 60 > 60  
Sexa 
        
0.139 
    Male 
        
 
        Cases (n)e 3 19 55 51 92 91 32 
 
 
        Multivariate model 0.66 (0.21-2.14) 1.2 (0.70-2.06) Reference 0.76 (0.51-1.11) 0.83 (0.59-1.17) 0.68 (0.48-0.97) 0.84 (0.52-1.35) 0.063  
    Female 
        
 
        Cases (n)e 39 12 81 74 33 13 0 
 
 
        Multivariate model 1.79 (1.18-2.72) 0.88 (0.47-1.63) Reference 0.70 (0.51-0.96) 0.89 (0.59-1.35) 1.33 (0.73-2.41) NA 0.013  
Hypertensionb 
        
0.404 
    No 
        
 
        Cases (n)e 19 17 92 69 76 58 20 
 
 
        Multivariate model 1.17 (0.69-1.97) 1.01 (0.59-1.73) Reference 0.59 (0.43-0.81) 0.70 (0.51-0.97) 0.57 (0.40-0.82) 0.83 (0.48-1.41) 0.003  
    Yes 
        
 
        Cases (n)e 22 14 41 48 43 42 12 
 
 
        Multivariate model 1.91 (1.10-3.32) 1.25 (0.67-2.32) Reference 0.97 (0.64-1.47) 1.19 (0.75-1.88) 1.20 (0.74-1.96) 1.27 (0.62-2.60) 0.513  
Smoking statusc 
        
0.787 
    Never 
        
 
        Cases (n)e 25 10 67 59 29 23 6 
 
 
        Multivariate model 1.23 (0.75-2.02) 0.81 (0.41-1.61) Reference 0.86 (0.60-1.22) 0.7 (0.44-1.10) 0.78 (0.46-1.32) 1.06 (0.43-2.59) 0.134  
    Former 
        
 
        Cases (n)e 8 12 31 35 46 36 12 
 
 
        Multivariate model 2.71 (1.21-6.08) 1.64 (0.82-3.26) Reference 0.73 (0.45-1.19) 0.95 (0.59-1.54) 0.79 (0.47-1.32) 1.28 (0.62-2.64) 0.073  
    Current 
        
 
        Cases (n)e 9 9 37 31 50 45 14 
 
 
        Multivariate model 1.53 (0.72-3.26) 0.90 (0.43-1.90) Reference 0.56 (0.35-0.91) 0.92 (0.59-1.43) 0.77 (0.48-1.23) 0.72 (0.36-1.42) 0.178  
Body mass indexd 
        
0.175 
    < 25 
        
 
        Cases (n)e 14 8 37 52 46 23 3 
 
 
        Multivariate model 2.55 (1.34-4.86) 1.37 (0.63-2.99) Reference 1.05 (0.68-1.61) 1.25 (0.79-1.97) 0.82 (0.46-1.44) 0.68 (0.20-2.29) 0.042  
    25 - <30 
        
 
        Cases (n)e 10 17 74 46 51 58 19 
 
 
        Multivariate model 0.66 (0.33-1.31) 1 .00(0.58-1.73) Reference 0.48 (0.33-0.70) 0.58 (0.39-0.84) 0.67 (0.46-0.99) 0.98 (0.56-1.72) 0.215  
    ≥ 30 
        
 
        Cases (n)e 18 6 25 27 28 23 10 
 
 
        Multivariate model 2.11 (1.09-4.07) 0.81 (0.32-2.02) Reference 0.98 (0.57-1.70) 1.20 (0.67-2.14) 0.85 (0.45-1.61) 0.93 (0.41-2.13) 0.167  
a Multivariate model with age at recruitment (continuous) as the time scale stratified by EPIC study center and adjusted by body mass index (categories: <18.5, 18.5-<25, 25-
<30, 30-<35, ≥35), smoking status (Never/Former/Current/Don’t know), hypertension (Yes/No/Don’t know), waist-to-hip ratio (quartiles) 
b Multivariate model with age at recruitment (continuous) as the time scale stratified by EPIC study center and adjusted by sex (Male, Female), body mass index (categories: 
<18.5, 18.5-<25, 25-<30, 30-<35, ≥35), smoking status (Never/Former/Current/Don’t know), waist-to-hip ratio (quartiles) 
c Multivariate model with age at recruitment (continuous) as the time scale stratified by EPIC study center and adjusted by sex (Male, Female), body mass index (categories: 
<18.5, 18.5-<25, 25-<30, 30-<35, ≥35), hypertension (Yes/No/Don’t know), waist-to-hip ratio (quartiles) 
d Multivariate model with age at recruitment (continuous) as the time scale stratified by EPIC study center and adjusted by sex (Male, Female), smoking status 
(Never/Former/Current/Don’t know), hypertension (Yes/No/Don’t know), waist-to-hip ratio (quartiles) 
e Number of cases indicates the number of cases with data available for the complete set of variables used in multivariable model and include all renal cancer subsites of renal 
parenchyma, renal pelvis, sarcoma and unclear or inconsistent subsite 
f Tests for trend were performed by ordinal coding of the variable under consideration 
gThe significance of interactions was assessed using likelihood ratio tests based on the models with and without the interaction terms 
 
